Literature DB >> 1355757

Two new human cholangiocarcinoma cell lines and their cytogenetics and responses to growth factors, hormones, cytokines or immunologic effector cells.

Y Shimizu1, A J Demetris, S M Gollin, P D Storto, H M Bedford, S Altarac, S Iwatsuki, R B Herberman, T L Whiteside.   

Abstract

Two new human cholangiocarcinoma (CC) cell lines (CC-SW-I and CC-LP-I) were established and maintained in culture for 2 years. Histologically, both original liver tumors were adenocarcinomas, and the cell lines exhibited morphologic features of moderately differentiated adenocarcinoma. Immunohistochemistry showed that both cell lines were strongly positive for cytokeratin AEI but negative for carbohydrate tumor-associated antigen, CA19-9. Ultrastructural analysis of both cell lines showed the presence of tight junctional complexes and focally formed microvilli. Both CC cell lines were tumorigenic in nude mice. Cytogenetic analysis showed that both cell lines expressed highly aneuploid karyotypes with numerous structural and numerical deviations. CC-SW-I was hypodiploid with numerous chromosome losses and structural rearrangements, while CC-LP-I was hyperdiploid and displayed multiple additional chromosomes. Doubling times for the CC-SW-I and CC-LP-I cell lines in the presence of 15% fetal bovine serum were 72 hr and 180 hr, respectively. Growth of the CC-SW-I cell line was significantly stimulated in the presence of insulin, while that of the CC-LP-I cell line was significantly augmented by epidermal growth factor (EGF). In contrast, dexamethasone strongly inhibited proliferation of both cell lines in a dose-dependent manner. Among various recombinant cytokines examined for effects on growth or surface antigen expression on CC cell lines, only interleukin I-beta (ILI-beta) strongly inhibited growth of the CC-LP-I cell line, while interferons (IFNs) or tumor necrosis factor-alpha (TNF-alpha) were mildly inhibitory. Both tumor cell lines were resistant to natural killer (NK) cells but sensitive to lymphokine-activated killer (LAK) cells. Preincubation of tumor cells with IFN-gamma, IFN-alpha or TNF-alpha significantly decreased the susceptibility of each tumor cell line to lysis by LAK cells, and the change in sensitivity did not correlate with the expression of HLA antigens or intercellular adhesion molecule-I (ICAM-I) on the surface of tumor cells. These 2 CC cell lines are expected to provide valuable information about cell biology of human CC.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1355757     DOI: 10.1002/ijc.2910520217

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  45 in total

1.  Neuropeptide Y inhibits cholangiocarcinoma cell growth and invasion.

Authors:  Sharon DeMorrow; Paolo Onori; Julie Venter; Pietro Invernizzi; Gabriel Frampton; Mellanie White; Antonio Franchitto; Shelley Kopriva; Francesca Bernuzzi; Heather Francis; Monique Coufal; Shannon Glaser; Giammarco Fava; Fanyin Meng; Domenico Alvaro; Guido Carpino; Eugenio Gaudio; Gianfranco Alpini
Journal:  Am J Physiol Cell Physiol       Date:  2011-01-26       Impact factor: 4.249

2.  Induction of insolubility by herpes simplex virus VP22 precludes intercellular trafficking of N-terminal Apoptin-VP22 fusion proteins.

Authors:  Saskia A Rutjes; Piter J Bosma; Jennifer L Rohn; Mathieu H M Noteborn; John G Wesseling
Journal:  J Mol Med (Berl)       Date:  2003-07-16       Impact factor: 4.599

3.  miR-24 Inhibition Increases Menin Expression and Decreases Cholangiocarcinoma Proliferation.

Authors:  Laurent Ehrlich; Chad Hall; Julie Venter; David Dostal; Francesca Bernuzzi; Pietro Invernizzi; Fanyin Meng; Jerome P Trzeciakowski; Tianhao Zhou; Holly Standeford; Gianfranco Alpini; Terry C Lairmore; Shannon Glaser
Journal:  Am J Pathol       Date:  2017-01-11       Impact factor: 4.307

4.  Interleukin-6-driven progranulin expression increases cholangiocarcinoma growth by an Akt-dependent mechanism.

Authors:  Gabriel Frampton; Pietro Invernizzi; Francesca Bernuzzi; Hae Yong Pae; Matthew Quinn; Darijana Horvat; Cheryl Galindo; Li Huang; Matthew McMillin; Brandon Cooper; Lorenza Rimassa; Sharon DeMorrow
Journal:  Gut       Date:  2011-11-07       Impact factor: 23.059

5.  Characterization of a novel rat cholangiocarcinoma cell culture model-CGCCA.

Authors:  Chun-Nan Yeh; Kun-Ju Lin; Tsung-Wen Chen; Ren-Ching Wu; Lee-Cheng Tsao; Ying-Tzu Chen; Wen-Hui Weng; Miin-Fu Chen
Journal:  World J Gastroenterol       Date:  2011-06-28       Impact factor: 5.742

6.  miR-34a-dependent overexpression of Per1 decreases cholangiocarcinoma growth.

Authors:  Yuyan Han; Fanyin Meng; Julie Venter; Nan Wu; Ying Wan; Holly Standeford; Heather Francis; Cynthia Meininger; John Greene; Jerome P Trzeciakowski; Laurent Ehrlich; Shannon Glaser; Gianfranco Alpini
Journal:  J Hepatol       Date:  2016-02-24       Impact factor: 25.083

7.  Inhibition of the apelin/apelin receptor axis decreases cholangiocarcinoma growth.

Authors:  Chad Hall; Laurent Ehrlich; Julie Venter; April O'Brien; Tori White; Tianhao Zhou; Tien Dang; Fanyin Meng; Pietro Invernizzi; Francesca Bernuzzi; Gianfranco Alpini; Terry C Lairmore; Shannon Glaser
Journal:  Cancer Lett       Date:  2016-11-26       Impact factor: 8.679

8.  Binding of tumour necrosis factor-alpha (TNF-alpha) to TNF-RI induces caspase(s)-dependent apoptosis in human cholangiocarcinoma cell lines.

Authors:  P Utaisincharoen; S Ubol; N Tangthawornchaikul; P Chaisuriya; S Sirisinha
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

9.  Establishment and characterization of a cholangiocarcinoma cell line (RMCCA-1) from a Thai patient.

Authors:  Panthip Rattanasinganchan; Kawin Leelawat; Sa-ard Treepongkaruna; Chintana Tocharoentanaphol; Somboon Subwongcharoen; Tuangporn Suthiphongchai; Rutaiwan Tohtong
Journal:  World J Gastroenterol       Date:  2006-10-28       Impact factor: 5.742

10.  Caffeic acid phenethyl ester decreases cholangiocarcinoma growth by inhibition of NF-kappaB and induction of apoptosis.

Authors:  Paolo Onori; Sharon DeMorrow; Eugenio Gaudio; Antonio Franchitto; Romina Mancinelli; Julie Venter; Shelley Kopriva; Yoshiyuki Ueno; Domenico Alvaro; Jennifer Savage; Gianfranco Alpini; Heather Francis
Journal:  Int J Cancer       Date:  2009-08-01       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.